Literature DB >> 27931616

MicroRNAs in Cardiovascular Disease.

Temo Barwari1, Abhishek Joshi1, Manuel Mayr2.   

Abstract

Micro-ribonucleic acids (miRNAs) are in the spotlight as post-transcriptional regulators of gene expression. More than 1,000 miRNAs are encoded in the human genome. In this review, we provide an introduction to miRNA biology and research methodology, and highlight advances in cardiovascular research to date. This includes the potential of miRNAs as therapeutic targets in cardiac and vascular disease, and their use as novel biomarkers. Although some miRNA therapies are already undergoing clinical evaluation, we stress the importance of integrating current knowledge of miRNA biology into a systemic context. Discovery studies focus on miRNA effects within one specific organ, whereas the expression of most miRNAs is not restricted to a single tissue. Because most miRNA-based therapies act systemically, this may preclude widespread clinical use. The development of more targeted interventions will bolster well-informed clinical applications, increasing the chances of success and minimizing the risk of setbacks for miRNA-based therapeutics. Copyright Â
© 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA therapeutic; biomarkers; genetic therapy; noncoding RNA

Mesh:

Substances:

Year:  2016        PMID: 27931616     DOI: 10.1016/j.jacc.2016.09.945

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  133 in total

Review 1.  MicroRNAs as Potential Pharmaco-targets in Ischemia-Reperfusion Injury Compounded by Diabetes.

Authors:  Hassan Dehaini; Hussein Awada; Ahmed El-Yazbi; Fouad A Zouein; Khodr Issa; Assaad A Eid; Maryam Ibrahim; Adnan Badran; Elias Baydoun; Gianfranco Pintus; Ali H Eid
Journal:  Cells       Date:  2019-02-12       Impact factor: 6.600

Review 2.  The circulating non-coding RNA landscape for biomarker research: lessons and prospects from cardiovascular diseases.

Authors:  Stępień E; Marina C Costa; Szczepan Kurc; Anna Drożdż; Nuno Cortez-Dias; Francisco J Enguita
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

3.  Direct screening of plasma circulating microRNAs.

Authors:  Paola Songia; Mattia Chiesa; Vincenza Valerio; Donato Moschetta; Veronika A Myasoedova; Yuri D'Alessandra; Paolo Poggio
Journal:  RNA Biol       Date:  2018-10-09       Impact factor: 4.652

Review 4.  Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention.

Authors:  Rui Guo; Sreejayan Nair
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-24       Impact factor: 5.187

5.  Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way.

Authors:  Jinyun Zhu; Kai Lu; Ning Zhang; Yun Zhao; Qunchao Ma; Jian Shen; Yinuo Lin; Pingping Xiang; Yaoliang Tang; Xinyang Hu; Jinghai Chen; Wei Zhu; Keith A Webster; Jian'an Wang; Hong Yu
Journal:  Artif Cells Nanomed Biotechnol       Date:  2017-11-16       Impact factor: 5.678

Review 6.  MicroRNAs as biomarkers for clinical studies.

Authors:  Igor P Pogribny
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-15

7.  Plasma MicroRNA Clusters in Human Left Ventricular Remodeling: A Biomarker and Discovery Platform.

Authors:  Arun Padmanabhan; Saptarsi M Haldar
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

Review 8.  Circadian MicroRNAs in Cardioprotection.

Authors:  Yoshimasa Oyama; Colleen Marie Bartman; Jennifer Gile; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

9.  Cardioinformatics: the nexus of bioinformatics and precision cardiology.

Authors:  Bohdan B Khomtchouk; Diem-Trang Tran; Kasra A Vand; Matthew Might; Or Gozani; Themistocles L Assimes
Journal:  Brief Bioinform       Date:  2020-12-01       Impact factor: 11.622

Review 10.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.